Legal entity name changes for manufacturing sites

Rachael O'Kane, Chetan Thakre and Nikita Uchil, Regulatory Affairs Specialists at G&L Scientific, explore why a Legal Entity Name Change (LENC) for manufacturing sites, though classified as an administrative variation, carries a level of strategic and operational complexity that is often significantly underestimated.

Mergers, acquisitions, and divestments routinely trigger a wave of downstream regulatory changes, and one of the most common is a change to the legal entity behind a product's manufacturing, packaging, or testing sites. 

On paper, this looks like one of the more straightforward activities in a regulatory lifecycle: no equipment moves, no process changes, no new comparability data. 

A name changes, a variation is filed, and the dossier is updated. 

In practice, a Legal Entity Name Change (LENC) affecting manufacturing sites is a multi-market, multi-workstream project with its own critical path, its own supply risk, and its own capacity to derail unrelated activities if it is not planned with the same rigour as a physical site transfer.

What triggers a site LENC?

Manufacturing site name changes are classified as administrative variations in most markets. Specifically, in the EU, they are classified under Category E.4, provided the change is purely administrative: name or address only, with no move of equipment, personnel, or physical operations. 

If any of these conditions change, the activity becomes a quality change with a different evidentiary and timeline profile. Where the Marketing Authorization Holder (MAH) itself only changes its name under the same legal entity, this classification applies there too; where a different legal entity takes over the MA, that is a Marketing Authorization Transfer (MAT) instead, following its own procedure. 

In most organizations the MAH change is managed locally, as it is typically a national administrative notification within each market's own registration, while the site LENC is coordinated centrally, since it changes the same CMC documentation underpinning each market in scope’s dossier. 

This article focuses solely on that central, site-level workstream.

A site LENC is rarely initiated by regulatory itself; it arrives as a downstream consequence of a corporate decision, and the first task is establishing exactly what has changed before classification work begins. Common triggers include:

• Acquisition of a manufacturing site or Contract Manufacturing Organization (CMO). Every product manufactured, tested, packaged, or released from there inherits a new legal entity on its manufacturing licence, regardless of who holds the Marketing Authorisations it supports.
• Divestment or carve-out of a manufacturing site. A site sold out of the current group takes on the acquiring entity's legal registration, independent of any change at MAH level.
• Intra-group restructuring, merger, demerger, spin-off, or legal entity conversion. Mergers or consolidation of manufacturing entities within the same parent, or a demerger, spin-off, or statutory conversion of the legal entity operating a site, can all change a site's registered legal entity even where the physical location, equipment, personnel, and operations remain unchanged.
• Corporate name change without a change in legal entity. The entity retains the same registration number and ownership but changes its legal name.
• Name and the trigger, the regulatory team's first task remains the same: Confirm the exact new legal name and registration number (where applicable), confirm whether the registration number itself has changed or only the name, and establish the legally effective date/implementation date. These facts determine the classification and set the LENC date around which the rest of the project is planned.

Mapping site function to regulatory impact

The first step in scoping a site LENC is understanding precisely what function each affected site performs and the registered site function within the respective marketing authorisations: finished product manufacturer, primary or secondary packager, QC testing site, and/or batch release site. This is not a formality, as the site’s function determines how the change impacts artwork, supply, and submission timelines.

• Batch release sites are the highest impact category. The release site name typically appears on the pack, so a LENC impacting a batch release site has direct consequences to artwork in most markets. Before committing a release site to the LENC scope, it is worth understanding if there is any agreement for the site to continue releasing under the old legal entity for a defined interim period. If so, this opens a genuine strategic choice:
  • Absorb the release site into the LENC wave and accept the associated artwork volume or
  • Keep the batch release element as a separate scope temporarily.
    • If keeping as a separate scope, close collaboration between site, regulatory, quality and supply is required to ensure continued supply and avoid commercially sensitive and patient-impacting “out of stock” situations.

• There may also be parallel variations to register an alternative batch release site to take over release, in which case, the batch release element may not need to progress as LENC but instead as a deletion of the site for the applicable function.
• Where only one release site is permitted for a given market, this decision needs to be made deliberately and early, since it shapes the whole submission sequence for that market.
• In some cases, LENC for a batch release site function may shift the scope of the change from an administrative variation to a new submission or instead may need to be managed via a Renewal. For example, Tajikistan manages this as a new submission, while Turkmenistan handles it via Renewal.
• Finished product manufacturers carry the same kind of artwork impact, but at a smaller scale. The finished product manufacturers’ name may be disclosed on the pack in some markets; however, this typically applies in fewer markets than those requiring batch release site name, making the trade-off less acute but still worth quantifying from artwork capability and supply point of view.
• Not every market requires disclosure of the release site at all, so the artwork and submission burden from batch release disclosure will not be uniform across the portfolio and should be mapped market-by- market rather than assumed, to ensure a full understanding when building the plan.
• Dual Certificate of Analysis (CoA). Another consideration for planning is whether the market accepts dual CoA listing both the old and new site names, and the acceptable timeline for transition. A possible resolution in some cases may be negotiation with the relevant Health Authority to seek an expanded grace period in line with the submission timeline.
• CEP and DMF cross-references. Where the LENC applies to a drug substance manufacturing site, and the site holds or is referenced in a Certificate of Suitability or Drug/Active Substance Master File, the timing and execution of the LENC variation needs to be carefully managed, ensuring the updated CEP/DMF is available when submission is planned, and whether it needs to be grouped with other changes related to the CEP/DMF updates.
  

Where the release site is included within the LENC wave of activity (rather than split out as a separate scope), its approval timeline is a useful anchor for the priority of submission waves, since it often has the most direct bearing on supply. 

However, this approach needs to be balanced against markets lacking dual CoA acceptance and those with hard implementation-linked submission deadlines (discussed below); a wave sequence built purely around the release site risks missing statutory windows or outrunning documentation acceptance elsewhere.

Artwork: The real critical path

Artwork is usually the critical path of a LENC project, even though the submission and approval timelines are what gets tracked. Several questions must be answered before the first variation is filed:

What grace period applies to stock already on market or in the supply chain?

• Can the product be released from the site prior to LENC approval continue to be sold under the old name for a defined period, and if so, what is the final date by which old artwork must be phased out?
• Can the product be manufactured under the old legal entity still be imported after approval, and for how long?
• Can the site continue to manufacture using old artwork for a period post-approval, or is new artwork required from the point of submission, and are mock-ups needed to support the filing?

Where the rules above are restrictive, how much stock needs to be built and released ahead of implementation to bridge the gap?

• For markets with no grace period, no import allowance, or no dual CoA acceptance, pre-built stock covering the period between old-artwork cut-off and new-artwork approval is required to avoid a supply interruption. This needs to be quantified market by market against demand, manufacturing lead time, and shelf life since under-building risks a stock-out and over-building ties up working capital and risks waste if the timeline shifts.

When does the artwork change request need to be raised? 

• This depends on the submission timeline, the expected approval timeline, and the grace period, worked out backwards from the point at which supply must switch. Raised too late, artwork becomes the bottleneck regardless of how quickly the regulatory submission itself progresses.

How does the change apply to shared packs?

• Shared packs need coordinated approval timing. Where several markets share a single pack, approvals need to land within a tight window of one another to prevent the slowest market in the group from dictating the timeline for all of them.

These questions are not unique to LENC, but they are frequently under-scoped because the activity is filed as a low-complexity administrative variation. The classification of the variation and the complexity of the supply transition it triggers are two different things.

The work before the submission: Prerequisites

A significant portion of LENC risk sits upstream of the actual variation filing, in the prerequisites that the regulatory team needs to secure before a submission can even be filed. 

Site registrations, local good manufacturing practice (GMP) recognition, and GMP clearance under the new legal entity are commonly required before the variation can progress, and the timeline for these prerequisites needs to be understood and built into the plan with the same discipline as the submission timeline itself, not treated as a background activity that needs no active management. 

This is particularly relevant in some MENA/Gulf markets, where site registration is a mandatory prerequisite before a regulatory change can even be submitted.

A particular friction point arises around the EU Manufacturing and Import Authorisation (MIA) and particularly, its Annex 8, the section of the MIA listing the specific products authorised for manufacture or import at that site.

The updated MIA reflecting the new legal entity may not automatically carry over the full scope of active product registrations listed against the site, and proof of an updated Annex 8 is often needed to support the LENC variation itself, a circular requirement, since that proof cannot exist ahead of MIA issuance.

In practice, this is usually worked through direct engagement with the Health Authority, and in some cases can be resolved via a letter of intent to submit the LENC variation, supported by evidence of the submissions or approvals already in progress, until the Annex 8 is formally updated to reflect the complete active scope.

Several markets also impose fixed time-bound obligations linked to the LENC implementation date, rather than to submission convenience. 

In the EU, where the release site is in scope, the E.4.b variation is a Type IA_IN and must be notified within 14 days of implementation; the practical implication is that site registrations, change requests, and supporting documentation such as Chamber of Commerce certificates and the MIA need to be progressed well ahead of time, with submission packages effectively pre-built and ready to file the moment the entity change takes legal effect. 

Singapore, by contrast, allows a six-month window post-LENC. Each market's clock needs to be identified individually and mapped against document readiness.

The broader supporting document package - Certificates of Pharmaceutical Product (CPP), GMP certificates, MIAs, declarations, and the Site Master File, along with their respective legalisation and/or notarisation - must be scoped market-by-market, since requirements and acceptable formats vary and lead times for receipt of the documents and in particular the legalisation stage, can be significant.

Some Health Authorities also require a physical sample of packaging reflecting the updated site name or label to support the LENC submission. 

The type of sample required, and the point in the process at which it must be provided, vary by market and should be confirmed early, and need to be built into the submission plan.

A less visible but very real driver of LENC complexity, separate from the formal prerequisites above, is the accuracy of the underlying dossier and Regulatory Information Management (RIM) data. 

Where lifecycle maintenance has not been fully systematic, the need to confirm the current registered site details for every market in scope can involve substantial checking and validation of the data on file before the true scope of the LENC can even be confirmed. 

Change requests need to be raised against the correct, verified scope and clearly understood before they are progressed in RIM.

Sequencing the submissions and the supply transition

With the site scope, artwork approach, and prerequisites understood, the submission plan can be built. A wave-based approach works well here. Where batch release is included within the LENC scope, registrations affected by the batch release change can be prioritised, before moving to registrations where batch release is not in scope. In any case, the general approach for the wave-based sequencing is as follows:

• EU markets 
• UK National and Switzerland 
• Rest of World (RoW) markets that do not require evidence of EU/reference market approval 
• RoW markets that do require evidence of EU/reference market approval
• RoW markets requiring a CPP - these will be split out based on the order and legalisation lead times.

Implementation-linked deadlines, as mentioned earlier, need to be managed against this sequence rather than assumed to fall naturally into place.

Within the EU, a supergrouping approach is usually the most efficient route where multiple member states and procedure types are involved, but it is worth confirming the exact scope early: the mix of centralised, MRP/DCP, and purely national registrations, together with how the manufacturing sites are registered by function across those procedures/registrations, supports construction of the supergrouping plan.

Selection of the Reference Member State (RMS) for the supergrouping (SG) is a strategic decision. 

Certain member states are more commonly used as lead RMS based on prior experience, review consistency, and engagement track record, and this should inform the choice. Caps on the number of MAs also need to be checked before the group is finalised: the Netherlands, for example, permits a maximum of 250 marketing authorisations within a single SG, of which no more than one hundred can be Dutch MAs, with the remaining 150 drawn from other markets. 

Constraints of this kind can force a portfolio to be split across multiple SG submissions rather than progressed as one and need to be identified early in the process to understand how the groupings should be structured and managed, rather than discovered at the point that the submission is built.

Letters of intent to obtain a SG number are best prepared two to three months ahead of the planned submission date, to avoid this becoming the pacing item for the whole EU wave.

Local dossier preparation timelines, once handed over from the core regulatory team to the market-level teams, and the approval timelines for the variation itself (including EU dependency where relevant) both need to feed back into the overall supply transition plan, alongside the grace period assumptions discussed earlier. 

Equally, the lead times for the prerequisites need to be validated rather than estimated, since a proposed submission date that has not been checked against realistic prerequisite timelines is a plan built on an assumption rather than on evidence.

The submission plan is critical to feed into the supply transition plan, which is used to ensure maintained supply. Therefore, further to all elements considered above, it is vital to understand the implementation status of a change: whether it is considered implemented before or after submission/approval.

Furthermore, the supply transition plan will outline any anticipated supply constraints and identify where bridging stocks will need to be built. 

This will need to be planned in consideration of the grace period, import, and old-artwork-manufacture questions raised earlier in Artwork: The Real Critical Path.

Managing the traffic around the LENC

A LENC rarely happens in isolation, and the interactions with other ongoing activities are a frequent source of delay that is easy to underestimate at the planning stage.

• Ongoing variations, renewals, and post-approval commitments in the same markets can interfere with submission timing, either by occupying the same CTD sections or by triggering a market's restriction on parallel submissions. Close coordination with affiliates and product owners is needed to sequence these correctly rather than discover the conflict at submission stage.
• Other variations that require a supporting Qualified Person (QP) declaration will need to reflect the updated site name if the GMP and MIA already reflect the new entity name. In these cases, depending on the urgency of the other variation, the LENC may need to be accelerated to facilitate the finalisation of the QP declaration and progression of the other variation.
• Site deletions are a distinct activity from a name change. As part of the initial assessment for which registrations are in scope of the LENC change, it may be determined that for some product portfolios, the site in question is no longer active for that product, and a site deletion, rather than LENC, needs to be progressed for that site. In some cases, it may be that only one of that site’s functions needs to be deleted and LENC is applicable for all other functions. This should be clearly outlined in the change request. In cases where both LENC and deletion are applicable for the one registration, these can be progressed as a grouped variation; however, in cases where only deletion is applicable, this should be actioned separately. The full scope of applicable changes needs to be mapped up front so that sites genuinely in LENC scope are prioritised correctly and effort is not spent progressing LENC variations for registrations that should instead be considered under the site deletion route.
• Competing priorities and priorities, whether driven by supply issues elsewhere in the portfolio or by the need to facilitate a different change, need a mechanism for being raised and assessed against the LENC plan without quietly eroding the sequencing logic that underpins the artwork and supply strategy.

Beyond the regulatory submission itself, a handful of adjacent items are easy to overlook but can surface late and cause disruption if they are not scoped alongside the core LENC plan:

• Contractual documentation. Quality agreements, technical agreements, and supply agreements between the sponsor and the affected sites typically reference the legal entity by name and may need updating in parallel, even though this sits outside the regulatory submission itself.
• Pharmacovigilance (PV) and QPPV references. Where the site or MAH name appears in the Pharmacovigilance System Master File or related PV documentation, this needs to be flagged to the PV function early, since it runs on its own governance track.

Conclusion

Classified correctly, a manufacturing site LENC is an administrative variation. Planned correctly, it is a cross-functional project with real supply risk, a genuine critical path through artwork, and enough interdependency with parallel lifecycle activity to disrupt timelines well beyond its own scope if it is not fully understood from the outset. 

The complexity does not sit in the regulatory classification; it sits in the sequencing, the prerequisites, the data underpinning the scope, and the coordination required to keep supply continuous while dozens of markets move through their own versions of the same change at different speeds.

Treating a LENC with the same planning discipline as a physical technology transfer, rather than as a routine administrative update, is what separates a smooth transition from a project that quietly consumes far more time and risk than its classification would suggest.

G&L Scientific has extensive experience supporting regulatory strategy and execution for acquisition and divestment driven changes, including legal entity name changes across global manufacturing networks. 

If you are planning a LENC and would like to discuss your specific scope, we would be happy to help.